var data={"title":"Phenytoin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Phenytoin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6774?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">see &quot;Phenytoin: Drug information&quot;</a> and <a href=\"topic.htm?path=phenytoin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Phenytoin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11284327\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular risk associated with rapid infusion (injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The rate of intravenous phenytoin administration should not exceed  50 mg/minute in adults and 1 to 3 mg/kg/minute (or 50 mg/minute, whichever is slower) in pediatric patients because of the risk of severe hypotension and cardiac arrhythmias. Careful cardiac monitoring is needed during and after administering intravenous phenytoin. Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or below the recommended infusion rate. Reduction in rate of administration or discontinuation of dosing may be needed.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209593\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dilantin;</li>\n      <li>Dilantin Infatabs;</li>\n      <li>Phenytek;</li>\n      <li>Phenytoin Infatabs</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209594\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dilantin;</li>\n      <li>Novo-Phenytoin;</li>\n      <li>Taro-Phenytoin;</li>\n      <li>Tremytoine Inj</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054953\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiarrhythmic Agent, Class I-B</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Hydantoin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444747\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Dosage should be individualized based upon clinical response and serum concentrations. Phenytoin base (eg, oral suspension, chewable tablets) contains ~8% more drug than phenytoin sodium (~92 mg base is equivalent to 100 mg phenytoin sodium). Dosage adjustments and closer serum monitoring may be necessary when switching dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Status epilepticus; neonatal seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Manufacturer labeling: IV: 15 to 20 mg/kg in a single or divided dose; then begin maintenance therapy usually 12 hours after dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alternate dosing: AAP recommendation: IV: 10 mg/kg in a single dose; then begin maintenance therapy usually 12 hours after dose. <b>Note:</b> Phenobarbital is the preferred treatment for treatment of neonatal seizures. Fosphenytoin is preferred over phenytoin if available due to lower risk of cardiac adverse effects (Hegenbarth 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Seizures; maintenance therapy:</b> IV, Oral: Initial: 5 mg/kg/day in 2 divided doses; usual range: 4 to 8 mg/kg/day in 2 divided doses; some patients may require dosing every 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054946\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">see &quot;Phenytoin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Dosage should be individualized based upon clinical response and serum concentrations; maintenance therapy dosage adjustments are typically not made more frequently than every 7 days. Phenytoin base (eg, oral suspension, chewable tablets) contains ~8% more drug than phenytoin sodium (~92 mg base is equivalent to 100 mg phenytoin sodium). Dosage adjustments and closer serum monitoring may be necessary when switching dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Status epilepticus:</b> Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer labeling: Loading dose: IV: 15 to 20 mg/kg in a single or divided dose; then begin maintenance therapy usually 12 hours after dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternate dosing: AAP, NCS recommendations: Loading dose: IV: 20 mg/kg in a single or divided doses; maximum dose: 1000 mg; then begin maintenance therapy usually 12 hours after dose (Brophy 2012; Hegenbarth 2008). An additional load of 5 to 10 mg/kg if status epilepticus is not resolved has been used; however, some experts recommend trying another agent once a total loading dose of 20 mg/kg has been given (Brophy 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Seizures:</b> Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Loading dose (if not previously on phenytoin): IV, Oral: 15 to 20 mg/kg; if currently on phenytoin, reloading dose should be based upon serum concentrations and recent dosing history; an oral loading dose should be divided into 3 doses and administered every 2-4 hours to decrease GI adverse effects and to ensure complete oral absorption</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\"> Maintenance therapy: IV, Oral: Initial: 5 mg/kg/day in divided doses (based upon dosage form, see below); usual range: 4 to 8 mg/kg/day; maximum daily dose: 300 mg/<b>day</b>. Some experts suggest higher maintenance doses (8 to 10 mg/kg/day) may be necessary in infants and young children (Guerrini 2006). Dosing should be based upon ideal body weight (IBW).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Usual dosing range (Bauer 1983; Chiba 1980; Suzuki 1994):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">6 months to 3 years: 8 to 10 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">4 to 6 years: 7.5 to 9 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">7 to 9 years: 7 to 8 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">10 to 16 years: 6 to 7 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dosing interval (product specific):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Immediate release preparations (including injection, suspension, and chewable tablets): Divide daily dose into 2 to 3 doses per day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Extended release preparations: In most pediatric patients, usually dosed every 12 hours; however, in adolescent patients with sufficiently long half-life, may be dosed every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Seizure prophylaxis, traumatic brain injury: </b> Limited data available; efficacy results variable: Infants, Children, and Adolescents: IV: Initial: 18 mg/kg over 20 minutes; followed by 6 mg/kg/day divided every 8 hours for 48 hours was used in a double-blind, placebo-controlled trial of 102 pediatric patients (n=46 treatment group; median age: 6.4 years) and showed no significance difference in seizure frequency between groups; however, the trial was stopped early due to a very low seizure frequency among both study groups (Young 2004). In a retrospective trial, reduced seizure frequency with prophylactic phenytoin use was described (Lewis 1993). <b>Note:</b> Current guidelines suggest that prophylactic phenytoin may be considered to reduce the incidence of early post-traumatic seizures in pediatric patients with severe traumatic brain injuries but it does not reduce the risk of long-term seizures or improve neurologic outcome (Kochanek 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: <b>Note:</b> Phenytoin base (eg, oral suspension, chewable tablets) contains ~8% more drug than phenytoin sodium (~92 mg base is equivalent to 100 mg phenytoin sodium). Dosage adjustments and closer serum monitoring may be necessary when switching dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Status epilepticus:</b> IV: Loading dose: Manufacturer recommends 10 to 15 mg/kg; however, 15 to 20 mg/kg at a maximum rate of 50 mg/minute is generally recommended (K&auml;lvi&auml;inen 2007; Lowenstein 2005); initial maintenance dose: IV, Oral: 100 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Anticonvulsant:</b> Oral: Loading dose: 15 to 20 mg/kg; consider prior phenytoin serum concentrations and/or recent dosing history if available; administer oral loading dose in 3 divided doses given every 2 to 4 hours to decrease GI adverse effects and to ensure complete oral absorption; initial maintenance dose: 300 mg/day in 3 divided doses; may also administer in 1 to 2 divided doses using extended release formulation; adjust dosage based on individual requirements; usual maintenance dose range: 300 to 600 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment: </b>Phenytoin serum concentrations may be difficult to interpret in renal failure. Monitoring of free (unbound) concentrations or adjustment to allow interpretation is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Safe in usual doses in mild liver disease; clearance may be substantially reduced in cirrhosis and plasma concentration monitoring with dose adjustment advisable. Free phenytoin concentrations should be monitored closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209562\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilantin: 30 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilantin: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Phenytek: 200 mg, 300 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 200 mg, 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (2 mL, 5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilantin: 125 mg/5 mL (237 mL) [orange-vanilla flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (4 mL, 237 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilantin Infatabs: 50 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Phenytoin Infatabs: 50 mg [scored; contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake, saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209547\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26964803\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">see &quot;Phenytoin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">The capsule dosage form represents <i>Extended Phenytoin Sodium Capsules,</i> USP, a designation differentiating the drug from <i>Prompt Phenytoin Sodium Capsules,</i> USP (no longer available) as the extended form was characterized by a slow and extended rate of absorption when the two were compared.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11441305\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Dilantin chewable extended release capsules:  <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/084427Orig1s032lbl.pdf#page=12&amp;token=GVGxq2qpAhw5GeWoRrIM7jlexDaTUIm66lwuC8qjPFY29ORPkSLaWgzZUN7EcexPFxtZO35GV2H0W+WXdQWQ2GbZHB0Wt6A4lCfQK+e9qwzboqpMTU0g3B/yGufXFs23&amp;TOPIC_ID=12702\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/084427Orig1s032lbl.pdf#page=12</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Dilantin-125 oral suspension:  <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008762s057s058lbl.pdf#page=18&amp;token=uzn7F/6WmYUkK+eqkfzkRrih0pVqre1Yllri/cSTf2LdK7/dUtyAsDQISe/hdtBV3wakPLiZNf/LzZtDfWzO1C4TEOHAgyvlwnQI2XAY42YGm6+JQrMAYQw6YCWDj8nJ&amp;TOPIC_ID=12702\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008762s057s058lbl.pdf#page=18</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054958\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release capsules: May be administered without regard to meals </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suspension: Shake well prior to use; measure and administer dose using a calibrated oral dosing syringe (or other accurate dose-measuring device). Absorption is impaired when phenytoin suspension is given concurrently to patients who are receiving continuous nasogastric feedings. A method to resolve this interaction is to divide the daily dose of phenytoin and withhold the administration of nutritional supplements for 1-2 hours before and after each phenytoin dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: <b>Note:</b> Fosphenytoin may be considered for loading in patients who are in status epilepticus, hemodynamically unstable, or develop hypotension/bradycardia with IV administration of phenytoin. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Phenytoin may be administered IV directly into a large vein through a large gauge needle or IV catheter; however, it is preferred that phenytoin be administered via infusion pump either undiluted or diluted in NS to prevent exceeding the maximum infusion rate (monitor closely for extravasation during infusion).  An in-line 0.22 to 0.55 micron filter is recommended for IVPB solutions due to the potential for precipitation of the solution.  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates: Administer slowly, usual maximum recommended rate: 0.5 to 1 mg/kg/minute (Hegenbarth 2008). <b>Note:</b> The  manufacturer recommends a maximum rate: 1 to 3 mg/kg/minute; however, a lower maximum rate of infusion of 1 mg/kg/minute has been recommended (Hanhan 2001; Hegenbarth 2008)  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants, Children, Adolescents, and Adults: Administer slowly, maximum recommended rate: 1 to 3 mg/kg/minute or maximum rate: 50 mg/minute, whichever is slower  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Following IV administration, NS should be injected through the same needle or IV catheter to prevent irritation. Avoid IM use due to erratic absorption, pain on injection, and precipitation of drug at injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. There is conflicting information regarding an antidote; some sources recommend not to use an antidote (Montgomery, 1999), while other sources recommend hyaluronidase (see Management of Drug Extravasations for more details). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\"></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133436\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving, a gown, and (if dosage form allows) CSTDs are required during IV administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209585\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect capsules from light. Protect capsules and tablets from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution for injection: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Use only clear solutions free of precipitate and haziness; slightly yellow solutions may be used. Precipitation may occur if solution is refrigerated and may dissolve at room temperature. Discard any unused product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054957\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Management of generalized tonic-clonic (grand mal) and complex partial seizures and the prevention of seizures following head trauma/neurosurgery [FDA approved in pediatric patients (age not specified) and adults]. Has also been used for simple partial seizures; ventricular arrhythmias, including those associated with digitalis intoxication, prolonged QT interval, and surgical repair of congenital heart diseases in children</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Management of status epilepticus of the grand mal type and prevention and treatment of seizures occurring during neurosurgery [FDA approved in neonatal and pediatric patients (age not specified) and adults]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209653\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Phenytoin may be confused with phenelzine, phentermine, PHENobarbital </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilantin may be confused with Dilaudid, dilTIAZem, Dipentum</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dilantin [US, Canada, and multiple international markets] may be confused with Dolantine brand name for pethidine [Belgium] </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209650\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial conduction depression (IV administration), bradycardia (IV administration), cardiac arrhythmia (IV administration), circulatory shock (IV administration), hypotension (IV administration), periarteritis nodosa, ventricular conduction depression (IV administration), ventricular fibrillation (IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Ataxia, cerebral atrophy (elevated serum levels and/or long-term use), cerebral dysfunction (elevated serum levels and/or long-term use), confusion, dizziness, drowsiness, headache, insomnia, mood changes, nervousness, paresthesia, peripheral neuropathy (associated with chronic treatment), slurred speech, twitching, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Bullous dermatitis, exfoliative dermatitis, hypertrichosis, morbilliform rash (most common), scarlatiniform rash, skin or other tissue necrosis (IV administration), skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperglycemia, increased gamma-glutamyl transferase, vitamin D deficiency (associated with chronic treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, dysgeusia (metallic taste), enlargement of facial features (lips), gingival hyperplasia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Peyronie disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, granulocytopenia, Hodgkin lymphoma, immunoglobulin abnormality, leukopenia, lymphadenopathy, macrocytosis, malignant lymphoma, megaloblastic anemia, pancytopenia, pseudolymphoma, purpuric dermatitis, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Acute hepatic failure, hepatic injury, hepatitis, increased serum alkaline phosphatase, toxic hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: DRESS syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (&quot;purple glove syndrome&quot;; edema, discoloration, and pain distal to injection site), local inflammation (IV administration), local irritation (IV administration), localized tenderness (IV administration), local tissue necrosis (IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Coarsening of facial features, osteomalacia, systemic lupus erythematosus, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Nystagmus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, tissue sloughing (IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Dyskinesia, hepatotoxicity (idiosyncratic) (Chalasani 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209570\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to phenytoin, other hydantoins, or any component of the formulation; concurrent use of delavirdine; history of prior acute hepatotoxicity attributable to phenytoin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Additional contraindications: Sinus bradycardia, sinoatrial block, second- and third-degree heart block, Adams-Stokes syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209551\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: A spectrum of hematologic effects have been reported (eg, agranulocytosis, leukopenia, granulocytopenia, thrombocytopenia, and pancytopenia with or without bone marrow suppression) and may be fatal; patients with a previous history of adverse hematologic reaction to any drug may be at increased risk. Early detection of hematologic change is important; advise patients of early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, petechial or purpuric hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone effects: Chronic use of phenytoin has been associated with decreased bone mineral density (osteopenia, osteoporosis, and osteomalacia) and bone fractures. Chronic use may result in decreased vitamin D concentrations due to hepatic enzyme induction and may lead to vitamin D deficiency, hypocalcemia, and hypophosphatemia; monitor as appropriate and consider implementing vitamin D and calcium supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: <b>[US Boxed Warning]: Phenytoin must be administered slowly. Intravenous administration should not exceed 50 mg/minute in adult patients. In pediatric patients, intravenous administration rate should not exceed 1-3 mg/kg/minute or 50 mg/minute whichever is slower.</b> Hypotension and severe cardiac arrhythmias (eg, heart block, ventricular tachycardia, ventricular fibrillation) may occur with rapid administration; adverse cardiac events have been reported at or below the recommended infusion rate. Cardiac monitoring is necessary during and after administration of intravenous phenytoin; reduction in rate of administration or discontinuation of infusion may be necessary. For nonemergency use, intravenous phenytoin should be administered more slowly; the use of oral phenytoin should be used whenever possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Severe reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (some fatal) have been reported; the onset of symptoms is usually within 28 days of treatment, but can occur later. Discontinue phenytoin if there are any signs of rash and evaluate for signs and symptoms of drug reaction with eosinophilia and systemic symptoms (DRESS). Data suggests a genetic susceptibility for serious skin reactions in patients of Asian descent (see &quot;Special populations&quot; below).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant (intravenous administration); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation. IV formulation may cause soft tissue irritation and inflammation, and skin necrosis at IV site; avoid IV administration in small veins. The &quot;purple glove syndrome&quot; (ie, discoloration with edema and pain of distal limb) may occur following peripheral IV administration of phenytoin. This syndrome may or may not be associated with drug extravasation. Symptoms may resolve spontaneously; however, skin necrosis and limb ischemia may occur; interventions such as fasciotomies, skin grafts, and amputation (rare) may be required. To decrease the risk of this syndrome, inject phenytoin slowly and directly into a large vein through a large gauge needle or IV catheter; follow with NS flushes through the same needle or IV catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported. Other manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and eosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. Immediately discontinue phenytoin in patients who develop acute hepatotoxicity and do not readminister.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Consider alternative therapy in patients who have experienced hypersensitivity to structurally similar drugs such as carboxamides (eg, carbamazepine), barbiturates, succinimides, and oxazolidinediones (eg, trimethadione).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lymphadenopathy: May occur (local or generalized), including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin disease; cause and effect relationship has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiorgan hypersensitivity reactions: Potentially serious, sometimes fatal multiorgan hypersensitivity reactions (also known as drug reaction with eosinophilia and systemic symptoms [DRESS]) have been reported with some antiepileptic drugs; including phenytoin; monitor for signs and symptoms of possible manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems; gradual discontinuation and conversion to alternate therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with underlying cardiac disease; IV use is contraindicated in patients with sinus bradycardia, sinoatrial block, or second and third degree heart block.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; phenytoin may inhibit insulin release and increase serum glucose in patients with diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; use free (unbound) serum concentrations to monitor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoalbuminemia: Use with caution in patients with any condition associated with low serum albumin levels, which will increase the free fraction of phenytoin in the serum and, therefore, the pharmacologic response. Use free (unbound) serum concentrations to monitor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Use with caution in patients with hypothyroidism; phenytoin may alter thyroid hormone serum concentrations (with chronic administration).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porphyria: May cause exacerbation of porphyria; use with caution in patients with porphyria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; use free (unbound) serum concentrations to monitor.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asian ancestry: Asian patients with the variant HLA-B*1502 may be at an increased risk of developing Stevens-Johnson syndrome and/or TEN. <b>Note:</b> Carbamazepine, another antiepileptic with a chemical structure similar to phenytoin, includes in the manufacturer labeling a recommendation to screen patients of Asian descent for the HLA-B*1502 allele prior to initiating therapy; this is not a current recommendation in the phenytoin manufacturer labeling. Patients with a positive result should avoid phenytoin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Critically-ill patients: Use with caution in critically ill patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in patients who are debilitated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not indicated for the treatment of absence seizures or seizures due to hypoglycemia or other metabolic causes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sustained serum concentrations: Plasma concentrations of phenytoin sustained above the optimal range may produce confusional states referred to as delirium, psychosis, or encephalopathy, or rarely, irreversible cerebellar dysfunction and/or cerebellar atrophy. Measure plasma phenytoin concentrations at the first sign of acute toxicity; dosage reduction is indicated if phenytoin concentrations are excessive; if symptoms persist, discontinue administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26059987\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In neonates, the FDA labeled maximum IV administration rate is 1 to 3 mg/kg/minute; <b>Note:</b> Most clinicians use a lower maximum rate of infusion in neonates: 0.5 to 1 mg/kg/minute; in infants and children: 1 to 3 mg/kg/minute. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Chronic use of phenytoin has been associated with decreased bone mineral density (osteopenia, osteoporosis, and osteomalacia) and bone fractures. Pediatric patients may be at increased risk for vitamin D deficiency; with chronic therapy, phenytoin may cause catabolism of vitamin D; the daily vitamin D requirement may be increased in these patients (&ge;400 units/day); vitamin D status should be periodically monitored with laboratory data (Misra, 2008; Wagner, 2008). May cause gingival overgrowth or hyperplasia; reported incidence up to 60%; some data suggest development is associated with higher doses and serum concentrations; folic acid supplementation (0.5 mg/day in pediatric patients &ge;6 years) may help to prevent or decrease gingival overgrowth; patients should be counseled regarding the importance of proper dental hygiene (Arya, 2011). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209639\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (major), CYP2C9 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP1A2 (weak), CYP2B6 (weak), CYP3A4 (strong), P-glycoprotein/ABCB1, UGT1A1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209556\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12702&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abiraterone Acetate.  Management: Avoid whenever possible.  If such a combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Acalabrutinib.  Management: Avoid co-administration of strong CYP3A inducers in patients taking acalabrutinib. If strong CYP3A inducers cannot be avoided, increase the dose of acalabrutinib to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: Fosphenytoin-Phenytoin may decrease the serum concentration of Acetaminophen. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.  Management: Per US labeling: if requiring chronic use of P-gp inducers, increase afatinib dose by 10mg as tolerated; reduce to original afatinib dose 2-3 days after stopping P-gp inducers.  Per Canadian labeling: avoid combination if possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Albendazole: Phenytoin may decrease serum concentrations of the active metabolite(s) of Albendazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of Phenytoin. Alcohol (Ethyl) may increase the serum concentration of Phenytoin. This may be particularly applicable with acute, heavy alcohol consumption. Alcohol (Ethyl) may decrease the serum concentration of Phenytoin. This may be particularly applicable with chronic, heavy alcohol consumption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: Phenytoin may decrease the serum concentration of Amiodarone. Amiodarone may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Phenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs. Phenytoin may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.<b> Exceptions: </b>Isavuconazonium Sulfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: CYP3A4 Inducers (Strong) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor. Reduce oral aripiprazole dose to 10-15 mg/day (for adults) if the inducer is discontinued. Avoid use of strong CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole Lauroxil: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Patients taking the 441 mg dose of aripiprazole lauroxil increase their dose to 662 mg if used with a strong CYP3A4 inducer for more than 14 days. No dose adjustment is necessary for patients using the higher doses of aripiprazole lauroxil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bazedoxifene: Phenytoin may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or, if bazedoxifene is combined with estrogen therapy, an increased risk of endometrial hyperplasia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzodiazepines: May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.<b> Exceptions: </b>ALPRAZolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Bictegravir.  Management: When possible consider using an alternative anticonvulsant with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bleomycin: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: Phenytoin may decrease the serum concentration of Boceprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brexpiprazole.  Management: If brexpiprazole is used together with a strong CYP3A4 inducer, the brexpiprazole dose should gradually be doubled over the course of 1 to 2 weeks.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brigatinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brivaracetam: Phenytoin may decrease the serum concentration of Brivaracetam. Brivaracetam may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: CYP3A4 Inducers (Strong) may decrease the serum concentration of BusPIRone.  Management: Consider alternatives to this combination. If coadministration of these agents is deemed necessary, monitor patients for reduced buspirone effects and increase buspirone doses as needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: Phenytoin may decrease the serum concentration of Busulfan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.  Management: Avoid use of strong CYP3A4 inducers with cabozantinib if possible. If combined, cabozantinib dose adjustments are recommended and vary based on the cabozantinib product used and the indication for use. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcifediol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Calcium Channel Blockers. Management: Avoid use of nimodipine or nifedipine with phenytoin. Monitor for phenytoin toxicity and/or decreased calcium channel blocker effects with any concurrent use.<b> Exceptions: </b>Clevidipine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: Phenytoin may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabidiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabidiol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: May increase the serum concentration of Phenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of CarBAMazepine. CarBAMazepine may increase the serum concentration of Phenytoin. Possibly by competitive inhibition at sites of metabolism.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically, the risk for osteomalacia or rickets may be increased.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cariprazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CeFAZolin: May decrease the protein binding of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ceritinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): Phenytoin may decrease the serum concentration of Chloramphenicol (Systemic). Phenytoin may increase the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorpheniramine: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Cimetidine may increase the serum concentration of Fosphenytoin-Phenytoin. Management: Consider using an alternative H<sub>2</sub>-antagonist to avoid this interaction. Monitor for toxic effects of hydantoin anticonvulsants if cimetidine is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May diminish the therapeutic effect of Phenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and may impair clarithromycin efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clindamycin (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Clindamycin (Systemic). Refer to the specific clindamycin (systemic) - rifampin drug interaction monograph for information concerning that combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ClonazePAM: Phenytoin may decrease the serum concentration of ClonazePAM. Clonazepam may also alter concentrations of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: Fosphenytoin-Phenytoin may decrease the serum concentration of Cobicistat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colesevelam: May decrease the serum concentration of Phenytoin. Management: Administer phenytoin at least 4 hours prior to colesevelam.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Copanlisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Copanlisib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Corticosteroids (Systemic). <b> Exceptions: </b>Hydrocortisone (Systemic); PrednisoLONE (Systemic); PredniSONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cosyntropin: May enhance the hepatotoxic effect of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Phenytoin may increase the metabolism of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inducers): CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates (High risk with Inducers).  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<b> Exceptions: </b>Benzhydrocodone; Buprenorphine; Etizolam; HYDROcodone; Zolpidem.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible. Closely monitor for decreased levels/effects of dabigatran if concomitantly administering P-glycoprotein inducers, particularly strong inducers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daclatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasabuvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Phenytoin may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Delamanid. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Phenytoin may decrease the serum concentration of Delavirdine. Delavirdine may increase the serum concentration of Phenytoin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): Phenytoin may decrease the serum concentration of Dexamethasone (Systemic). Dexamethasone (Systemic) may decrease the serum concentration of Phenytoin. Dexamethasone (Systemic) may increase the serum concentration of Phenytoin.  Management: Consider dexamethasone dose increases when combined with phenytoin and monitor closely for reduced steroid efficacy. Monitor phenytoin levels closely when combined with dexamethasone, both increased and decreased phenytoin levels have been reported.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: May increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May decrease the serum concentration of Phenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diethylstilbestrol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Diethylstilbestrol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: Phenytoin may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May increase the serum concentration of Phenytoin. Management: Avoid concomitant use of disulfiram and phenytoin when possible.  Phenytoin dose adjustment will likely be necessary when starting and/or stopping concurrent disulfiram.  Monitor phenytoin response and concentrations closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Dolutegravir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Fosphenytoin-Phenytoin may decrease the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to strong CYP3A4 inducers in patients treated with doxorubicin. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to P-glycoprotein inducers in patients treated with doxorubicin whenever possible. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxycycline: Phenytoin may decrease the serum concentration of Doxycycline. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: Phenytoin may decrease the serum concentration of Efavirenz. Efavirenz may increase the serum concentration of Phenytoin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elbasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elbasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Elvitegravir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Erlotinib. Management: Avoid use of erlotinib with phenytoin when possible. If required, increase erlotinib dose by 50 mg increments at 2 week intervals, as tolerated, to a max of 450 mg/day.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eslicarbazepine: Phenytoin may decrease the serum concentration of Eslicarbazepine. Eslicarbazepine may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Estriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Topical): CYP3A4 Inducers (Strong) may decrease the serum concentration of Estriol (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Phenytoin may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal means of contraception is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethosuximide: May enhance the CNS depressant effect of Phenytoin. Phenytoin may decrease the serum concentration of Ethosuximide. Ethosuximide may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etizolam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide.  If these combinations cannot be avoided, monitor patients closely for diminished etoposide response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide Phosphate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide Phosphate.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide phosphate.  If these combinations cannot be avoided, monitor patients closely for diminished etoposide phosphate response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: Phenytoin may decrease the serum concentration of Etravirine.  Management: The manufacturer of etravirine states these drugs should not be used in combination<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Evogliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ezogabine: Fosphenytoin-Phenytoin may decrease the serum concentration of Ezogabine.  Management: Consider increasing the ezogabine dose when adding phenytoin.  Patients using this combination should be monitored closely for evidence of adequate ezogabine therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbamate: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Felbamate. Management: Decreased phenytoin dose will likely be needed when adding felbamate; some reports suggest an empiric 20% decrease in phenytoin dose. Additional reductions may be needed if felbamate dose is increased or as otherwise guided by monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floxuridine: May increase the serum concentration of Phenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Phenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunarizine: Phenytoin may decrease the serum concentration of Flunarizine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Systemic): May increase the serum concentration of Phenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Topical): May increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: May increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Folic Acid: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: May decrease the serum concentration of Phenytoin. The active amprenavir metabolite is likely responsible for this effect. Phenytoin may increase the serum concentration of Fosamprenavir. Specifically, phenytoin may increase the concentration of the active metabolite amprenavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fotemustine: Fosphenytoin-Phenytoin may decrease the serum concentration of Fotemustine. Fotemustine may decrease the serum concentration of Fosphenytoin-Phenytoin. Specifically, fotemustine may decrease concentrations of orally administered phenytoin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse reactions, increase gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers; resume 250 mg dose 7 days after discontinuation of the strong inducer.  Carefully monitor clinical response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemigliptin: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Gemigliptin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gestrinone: Fosphenytoin-Phenytoin may decrease the serum concentration of Gestrinone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Grazoprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Increase the guanfacine dose by up to double when initiating concomitant therapy with strong CYP3A4 inducers. Increase guanfacine dose gradually over 1-2 weeks if strong CYP3A4 inducer therapy is just beginning.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Halothane: May increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): Phenytoin may decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b> Exceptions: </b>Pitavastatin; Rosuvastatin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydrocortisone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Idelalisib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irinotecan Products: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Strong) may decrease isavuconazole serum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: May increase the serum concentration of Phenytoin. Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixazomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixazomib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Phenytoin may decrease the serum concentration of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: Phenytoin may decrease the serum concentration of LamoTRIgine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LevETIRAcetam: Fosphenytoin-Phenytoin may decrease the serum concentration of LevETIRAcetam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Phenytoin may diminish the therapeutic effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levomefolate: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Phenytoin may enhance the adverse/toxic effect of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Phenytoin may diminish the diuretic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: Phenytoin may decrease the serum concentration of Lopinavir. Lopinavir may decrease the serum concentration of Phenytoin.  Management: The manufacturer of lopinavir/ritonavir recommends avoiding once-daily administration if used together with phenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumefantrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macitentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inducers. If combined, monitor closely for decreased manidipine effects and loss of efficacy. Increased manidipine doses may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mebendazole: Phenytoin may decrease the serum concentration of Mebendazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meperidine: Phenytoin may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Phenytoin may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may increase the serum concentration of Methotrexate. Specifically, fosphenytoin-phenytoin may displace methotrexate from serum proteins, increasing the concentration of free, unbound drug.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylfolate: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MethylPREDNISolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): Phenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyraPONE: Phenytoin may decrease the serum concentration of MetyraPONE. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mexiletine: Phenytoin may decrease the serum concentration of Mexiletine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Phenytoin. Phenytoin may decrease the serum concentration of Mianserin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miconazole (Oral): May increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midostaurin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midostaurin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MiFEPRIStone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirodenafil.  Management: Consider avoiding the concomitant use of mirodenafil and strong CYP3A4 inducers. If combined, monitor for decreased mirodenafil effects. Mirodenafil dose increases may be required to achieve desired effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naldemedine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Nelfinavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Netupitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Fosphenytoin-Phenytoin may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of NIFEdipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Combined Inducers of CYP3A4 and P-glycoprotein may decrease the serum concentration of Nintedanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omeprazole: Phenytoin may decrease the serum concentration of Omeprazole. Omeprazole may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osimertinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osimertinib. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palbociclib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paliperidone: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Paliperidone.  Management: Avoid using the 3-month extended-release injectable suspension (Invega Trinza) with inducers of both CYP3A4 and P-glycoprotein during the 3-month dosing interval if possible. If combination is necessary, consider using extended-release tablets.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: Phenytoin may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with phenytoin/fosphenytoin.  Patients receiving this combination should be followed closely for response, especially with any changes to phenytoin/fosphenytoin therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Phenytoin may enhance the CNS depressant effect of PHENobarbital. PHENobarbital may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylbutazone: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimavanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pimavanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piperaquine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Piperaquine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pitolisant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Platinum Derivatives: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PONATinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PrednisoLONE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Phenytoin may increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Phenytoin may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of Propacetamol. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of its toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyridoxine: May increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QUEtiapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine.  Management: An increase in quetiapine dose (as much as 5 times the regular dose) may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7-14 days of discontinuing the inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Phenytoin may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: Phenytoin may decrease the serum concentration of QuiNINE. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Radotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Radotinib.  Management: Consider alternatives to this combination when possible as the risk of radotinib treatment failure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Reboxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ribociclib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Phenytoin. Management: Seek alternatives when possible. If used together, monitor closely for decreased serum phenytoin concentrations following rifampin initiation/dose increase, or increased concentrations and toxic effects following rifampin discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Phenytoin may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: Phenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rolapitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rolapitant.  Management: Avoid rolapitant use in patients requiring chronic administration of strong CYP3A4 inducers.  Monitor for reduced rolapitant response and the need for alternative or additional antiemetic therapy even with shorter-term use of such inducers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Rufinamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ruxolitinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sertraline: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Sertraline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus.  Management: Avoid concomitant use of strong CYP3A4 inducers and sirolimus if possible. If combined, monitor for reduced serum sirolimus concentrations. Sirolimus dose increases will likely be necessary to prevent subtherapeutic sirolimus levels.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sofosbuvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May decrease the serum concentration of Phenytoin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfamethoxazole: May increase the serum concentration of Phenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulthiame: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Phenytoin may decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen.  Management: Consider alternatives to concomitant use of strong CYP3A4 inducers and tamoxifen. If the combination cannot be avoided, monitor for reduced therapeutic effects of tamoxifen.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tasimelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tasimelteon. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: May increase the serum concentration of Fosphenytoin-Phenytoin. Management: Phenytoin dose reductions may be necessary when used together with fluorouracil, which is the active metabolite of tegafur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Telaprevir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: Phenytoin may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree).  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as phenytoin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teniposide: Phenytoin may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with phenytoin and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Alafenamide: Fosphenytoin-Phenytoin may decrease the serum concentration of Tenofovir Alafenamide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Phenytoin may decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of Phenytoin.  Management: Seek alternatives when possible. If used together, monitor for decreased concentrations/effects of phenytoin or theophylline if the other agent is initiated/dose increased, or increased concentrations/effects if the other is discontinued/dose decreased.<b> Exceptions: </b>Dyphylline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiothixene: Fosphenytoin-Phenytoin may decrease the serum concentration of Thiothixene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Phenytoin may decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiaGABine: CYP3A4 Inducers (Strong) may decrease the serum concentration of TiaGABine.  Management: Approximately 2-fold higher tiagabine doses and a more rapid dose titration will likely be required in patients concomitantly taking a strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticlopidine: May increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: Phenytoin may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Phenytoin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Topiramate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: Fosphenytoin-Phenytoin may decrease the serum concentration of Topotecan.  Management: Monitor topotecan response closely, and consider alternatives to phenytoin when possible.  No specific guidelines for topotecan dose adjustment are available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraZODone: Phenytoin may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Trimethoprim. Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tropisetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tropisetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May decrease the protein binding of Fosphenytoin-Phenytoin. This appears to lead to an initial increase in the percentage of unbound (free) phenytoin and to a decrease in total phenytoin concentrations.  Whether concentrations of free phenytoin are increased is unclear. With long-term concurrent use, total phenytoin concentrations may increase. Fosphenytoin-Phenytoin may decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.  Management: Avoid concurrent use of vemurafenib with a strong CYP3A4 inducer and replace with another agent when possible. If a strong CYP3A4 inducer is indicated and unavoidable, the dose of vemurafenib may be increased by 240 mg (1 tablet) as tolerated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inducers (Strong) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vigabatrin: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.  Management: Consider increasing vilazodone dose by as much as 2-fold (do not exceed 80 mg/day), based on response, in patients receiving strong CYP3A4 inducers for &gt; 14 days.  Reduce to the original vilazodone dose over 1-2 weeks after inducer discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine: Phenytoin may decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vindesine: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Phenytoin may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Phenytoin.  Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vortioxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vortioxetine.  Management: Consider increasing the vortioxetine dose to no more than 3 times the original dose when used with a strong drug metabolism inducer for more than 14 days. The vortioxetine dose should be returned to normal within 14 days of stopping the strong inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zaleplon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zaleplon.  Management: Consider the use of an alternative hypnotic that is not metabolized by CYP3A4 in patients receiving strong CYP3A4 inducers. If zalephon is combined with a strong CYP3A4 inducer, monitor for decreased effectiveness of zaleplon.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zonisamide: Phenytoin may decrease the serum concentration of Zonisamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209588\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ethanol: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acute use: Ethanol inhibits metabolism of phenytoin and may also increase CNS depression. Management: Monitor patients. Caution patients about effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chronic use: Ethanol stimulates metabolism of phenytoin. Management: Monitor patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Food: If phenytoin is administered with enteral feeding preparations and/or related nutritional supplements, serum concentrations of phenytoin may be decreased. Management: Do not administer phenytoin concomitantly with an enteral feeding preparation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209573\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Phenytoin crosses the placenta (Harden and Pennell 2009). An increased risk of congenital malformations and adverse outcomes may occur following <i>in utero</i> phenytoin exposure. Reported malformations include orofacial clefts, cardiac defects, dysmorphic facial features, nail/digit hypoplasia, growth abnormalities including microcephaly, and mental deficiency. Isolated cases of malignancies (including neuroblastoma) and coagulation defects in the neonate (may be life threatening) following delivery have also been reported. Maternal use of phenytoin should be avoided when possible to decrease the risk of cleft palate and poor cognitive outcomes. Polytherapy may also increase the risk of congenital malformations; monotherapy is recommended (Harden and Meader 2009). The maternal use of folic acid throughout pregnancy is recommended to reduce the risk of major congenital malformations (Harden and Pennell 2009). Potentially life-threatening bleeding disorders in the newborn may also occur due to decreased concentrations of vitamin K-dependent clotting factors following phenytoin exposure in utero; vitamin K administration to the mother prior to delivery and the newborn after birth is recommended.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Total plasma concentrations of phenytoin are decreased in the mother during pregnancy; unbound plasma (free) concentrations are also decreased and plasma clearance is increased. Due to pregnancy-induced physiologic changes, women who are pregnant may require dose adjustments of phenytoin in order to maintain clinical response; monitoring during pregnancy should be considered (Harden and Pennell 2009). For women with epilepsy who are planning a pregnancy in advance, baseline serum concentrations should be measured once or twice prior to pregnancy during a period when seizure control is optimal. Monitoring can then be continued once each trimester during pregnancy and postpartum; more frequent monitoring may be needed in some patients. Monitoring of unbound plasma concentrations is recommended (Patsalos 2008). In women taking phenytoin who are trying to avoid pregnancy, potentially significant interactions may exist with hormone-containing contraceptives; consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Patients exposed to phenytoin during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at https:\\\\aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054952\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, liver function, suicidality (eg, suicidal thoughts, depression, behavioral changes), bone growth or BMD and vitamin D status (chronic use; particularly pediatric patients)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Serum phenytoin concentrations: If available, free phenytoin concentrations should be obtained in patients with hyperbilirubinemia, renal impairment, uremia, or hypoalbuminemia; in adult patients, if free phenytoin concentrations are unavailable, the adjusted total concentration may be determined based upon equations. Trough serum concentrations are generally recommended for routine monitoring. To ensure therapeutic concentration is attained, peak serum concentrations may be measured 1 hour after the end of an IV infusion (particularly after a loading dose).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Additional monitoring with IV use: Continuous cardiac monitoring (rate, rhythm, blood pressure) and clinical observation during administration is recommended; blood pressure and pulse should be monitored every 15 minutes for 1 hour after administration with nonemergency use (Meek 1999); emergency use may require more frequent monitoring and for a longer time after administration; infusion site reactions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054956\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timing of serum samples: Because phenytoin is slowly absorbed, peak serum concentrations may occur 4-8 hours after ingestion of an oral dose. The apparent serum half-life varies with the dosage and the drug follows Michaelis-Menten kinetics. In adults, the average apparent half-life is about 24 hours; in pediatric patients, the apparent half-life is age-dependent (longer in neonates). Steady-state concentrations are reached in 5-10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toxicity is measured clinically, and some patients may require levels outside the suggested therapeutic range.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic range:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total phenytoin:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates: 8-15 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pediatric patients &ge;1 month and Adults: 10-20 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Concentrations of 5-10 mcg/mL may be therapeutic for some patients, but concentrations &lt;5 mcg/mL are not likely to be effective</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">50% of adult patients show decreased frequency of seizures at concentrations &gt;10 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">86% of adult patients show decreased frequency of seizures at concentrations &gt;15 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Add another anticonvulsant if satisfactory therapeutic response is not achieved with a phenytoin concentration of 20 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Free phenytoin: 1-2.5 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Total phenytoin:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Toxic:</i> &gt;30 mcg/mL (SI: &gt;119 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lethal:</i> &gt;100 mcg/mL (SI: &gt;400 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>When to draw serum concentrations:</b> This is dependent on the disease state being treated and the clinical condition of the patient.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Key points:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Slow absorption of extended capsules and prolonged apparent half-life minimize fluctuations between peak and trough concentrations, thus timing of sampling is not crucial.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Trough concentrations are generally recommended for routine monitoring (capsules, oral suspension, chewable tablets, and intermittent IV dosing). Daily levels are not necessary and may result in incorrect dosage adjustments. If it is determined essential to monitor free phenytoin concentrations, concomitant monitoring of total phenytoin concentrations is not necessary and expensive.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">After a loading dose: If rapid therapeutic serum concentrations are needed, initial concentrations may be drawn after 1 hour (after end of IV loading dose) or within 24 hours (after last oral loading dose) to aid in determining maintenance dose or need to reload.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Early assessment of serum concentrations: Draw within 2-3 days of therapy initiation to ensure that the patient's metabolism is not remarkably different from that which would be predicted by average literature-derived pharmacokinetic parameters; early serum concentrations should be used cautiously in design of new dosing regimens.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second concentration: Draw within 6-7 days with subsequent doses of phenytoin adjusted accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If plasma concentrations have not changed over a 3- to 5-day period, monitoring interval may be increased to once weekly in the acute clinical setting. In stable patients requiring long-term therapy, generally monitor levels at 3- to 12-month intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adjustment of serum concentration:</b> See tables.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Although it is ideal to obtain free phenytoin concentrations to assess serum concentrations in patients with hypoalbuminemia or renal failure (CrCl &le;10 mL/minute), it may not always be possible. If free phenytoin concentrations are unavailable, the following equations may be utilized in adult patients.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Adjustment of Serum Concentration in Adults With Low Serum Albumin</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Measured Total Phenytoin Concentration</p>\n            <p style=\"text-indent:0em;\">(mcg/mL)</p></th>\n          <th colspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Adult Patient's Serum Albumin (g/dL)</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">3.5</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">3</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">2</p></th></tr>\n        <tr>\n          <th colspan=\"4\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Adjusted Total Phenytoin Concentration (mcg/mL)<sup>1</sup></p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td colspan=\"5\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>\n                <sup>1</sup>Adjusted concentration = measured total concentration divided by [(0.2 x albumin) + 0.1].</b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">13</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">14</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">17</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">19</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">21</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30</p></td></tr></tbody></table>\n    \n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Adjustment of Serum Concentration in Adults With Renal Failure (CrCl &le;10 mL/min)</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Measured Total Phenytoin Concentration</p>\n            <p style=\"text-indent:0em;\">(mcg/mL)</p></th>\n          <th colspan=\"5\" align=\"center\">\n            <p style=\"text-indent:0em;\">Adult Patient's Serum Albumin (g/dL)</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">4</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">3.5</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">3</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">2</p></th></tr>\n        <tr>\n          <th colspan=\"5\" align=\"center\">\n            <p style=\"text-indent:0em;\">Adjusted Total Phenytoin Concentration (mcg/mL)<sup>1</sup></p></th></tr>\n        <tr>\n          <th colspan=\"6\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>Adjusted concentration = measured total concentration divided by [(0.1 x albumin) + 0.1].</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">13</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">14</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">17</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">22</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">29</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">33</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">33</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">38</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">43</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209550\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses; prolongs effective refractory period and suppresses ventricular pacemaker automaticity, shortens action potential in the heart</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209569\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IV: ~0.5 to 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Slow, variable; dependent on product formulation; decreased in neonates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: Premature: 1 to 1.2 L/kg; Full-term: 0.8 to 0.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 0.7 to 0.8 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 0.7 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.6 to 0.7 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: &ge;80% (&le;20% free)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: &ge;85% (&le;15% free)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 90% to 95%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Others: Decreased protein binding</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Disease states resulting in a decrease in serum albumin concentration</i>: Burns, hepatic cirrhosis, nephrotic syndrome, pregnancy, cystic fibrosis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Disease states resulting in an apparent decrease in affinity of phenytoin for serum albumin</i>: Renal failure, jaundice (severe), other drugs (displacers), hyperbilirubinemia (total bilirubin &gt;15 mg/dL), CrCl &lt;25 mL/minute (unbound fraction is increased two- to threefold in uremia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Follows dose-dependent (Michaelis-Menten) pharmacokinetics; &ldquo;apparent&rdquo; or calculated half-life is dependent upon serum concentration, therefore, metabolism is best described in terms of V<sub>max</sub> (metabolic capacity) and K<sub>m</sub> (constant equal to the concentration at which the rate of metabolism is &frac12; of V<sub>max</sub>); V<sub>max</sub> is increased in infants &gt;6 months and children compared to adults; major metabolite (via oxidation) HPPA undergoes enterohepatic recycling and elimination in urine as glucuronides</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Formulation dependent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Range: 7 to 42 hours; newborns (PNA &lt;7 days): Apparent half-life greatly prolonged (clearance decreased) and then rapidly accelerates to infant levels by 5 weeks of life. <b>Note:</b> Elimination is not first-order (ie, follows Michaelis-Menten pharmacokinetics); half-life increases with increasing phenytoin concentrations; best described using parameters such as V<sub>max</sub> and K<sub>m</sub>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum (formulation dependent): Oral: Extended-release capsule: 4 to 12 hours; Immediate release preparation: 1.5 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;5% as unchanged drug); as glucuronides</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Highly variable, dependent upon intrinsic hepatic function and dose administered; increased clearance and decreased serum concentrations with febrile illness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209572\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Dilantin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $127.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $148.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Phenytek Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $50.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $75.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Phenytoin Sodium Extended Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $64.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $45.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $67.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Dilantin Infatabs Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $138.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Phenytoin Infatabs Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $52.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Phenytoin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $52.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Phenytoin Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (2 mL): $2.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Dilantin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (237 mL): $184.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Phenytoin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (237 mL): $34.10</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209576\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aleviatin (JP, TW);</li>\n      <li>Antisacer (PT);</li>\n      <li>Clerin (PY);</li>\n      <li>Clerin LR (PY);</li>\n      <li>Cumatil (CO);</li>\n      <li>Decatona (ID);</li>\n      <li>Di-Hydan (FR, LU, VN);</li>\n      <li>Difetoin (HR);</li>\n      <li>Dilantin (AU, BB, FR, HK, ID, IN, MY, NZ, PH, PK, SG, TH, VE, VN);</li>\n      <li>Dintoina (IT);</li>\n      <li>Diphedan (BD, HU);</li>\n      <li>Ditoin (HK, MY, TH);</li>\n      <li>Dyfenin (UA);</li>\n      <li>Epamin (AR, BO, BR, CL, CO, CR, DO, EC, GT, HN, MX, NI, PA, PE, PR, SV, VE);</li>\n      <li>Epanutin (AE, AT, BE, BF, BH, BJ, CI, CY, CZ, DE, EG, ES, ET, FI, GB, GH, GM, GN, GR, HU, IE, IL, IQ, IR, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, NE, NG, NL, OM, PL, QA, SA, SC, SD, SE, SL, SN, SY, TN, TR, TZ, UG, UY, YE, ZA, ZM, ZW);</li>\n      <li>Epilan-D (AT, BG, CZ);</li>\n      <li>Epilax (BD);</li>\n      <li>Epinat (NO);</li>\n      <li>Epinotid (LK);</li>\n      <li>Epinotin (LK);</li>\n      <li>Eptoin (IN);</li>\n      <li>Felantin (PE);</li>\n      <li>Fenatoin NM (SE);</li>\n      <li>Fenevit (PH);</li>\n      <li>Fenidantoin S (MX);</li>\n      <li>Fenitin (PH);</li>\n      <li>Fenitron (MX);</li>\n      <li>Fenytoin (DE, DK);</li>\n      <li>Fomiken (MX);</li>\n      <li>Hidanil (CO);</li>\n      <li>Hidantin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Hidanto&iacute;na (MX);</li>\n      <li>Hydantin (FI);</li>\n      <li>Hydantoin (KR);</li>\n      <li>Hydantol (JP);</li>\n      <li>Ikaphen (ID);</li>\n      <li>Kutoin (ID);</li>\n      <li>Lantidin (PH);</li>\n      <li>Lehydan (SE);</li>\n      <li>Pepsytoin-100 (TH);</li>\n      <li>Phenhydan (AT, CH, DE, EE, HU, LU);</li>\n      <li>Phenilep (ID);</li>\n      <li>Phenlin (TW);</li>\n      <li>Phentolep (JO, QA);</li>\n      <li>Pyoredol (AR, FR);</li>\n      <li>Sinergina (ES);</li>\n      <li>Sizatoin (BD);</li>\n      <li>Utoin (TH);</li>\n      <li>Xentoin (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abernethy DR and Greenblatt DJ, &quot;Phenytoin Disposition in Obesity. Determination of Loading Dose,&quot; <i>Arch Neurol</i>, 1985, 42(5):468-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/3994563/pubmed\" target=\"_blank\" id=\"3994563\">3994563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arya R, Gulati S, Kabra M, et al, &quot;Folic Acid Supplementation Prevents Phenytoin-Induced Gingival Overgrowth in Children,&quot; <i>Neurology</i>, 76(15):1338-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/21482950/pubmed\" target=\"_blank\" id=\"21482950\">21482950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Au Yeung SC and Ensom MH, &quot;Phenytoin and Enteral Feedings: Does Evidence Support an Interaction?&quot; <i>Ann Pharmacother</i>, 2000, 34(7-8):896-905.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/10928402/pubmed\" target=\"_blank\" id=\"10928402\">10928402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer LA and Blouin RA, &ldquo;Phenytoin Michaelis-Menten Pharmacokinetics in Caucasian Pediatric Patients,&rdquo; <i>Clin Pharmacokinet</i>, 1983, 8(6):545-9. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/6653035/pubmed\" target=\"_blank\" id=\"6653035\">6653035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Black J, Hannaman T, and Malone C, &quot;The Relationship of Serum Albumin Level to Phenytoin Toxicity,&quot; <i>J Clin Pharmacol</i>, 1987, 27(3):249-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/3680582/pubmed\" target=\"_blank\" id=\"3680582\">3680582</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al, &quot;Guidelines for the Evaluation and Management of Status Epilepticus,&quot; <i>Neurocrit Care</i>, 2012, 17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.  <a>http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chiba K, Ishizaki T, Miura H, et al, &ldquo;Michaelis-Menten Pharmacokinetics of Diphenylhydantoin and Application in the Pediatric Age Patient,&rdquo; <i>J Pediatr</i>, 1980, 96(3 Pt 1):479-84. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/7359247/pubmed\" target=\"_blank\" id=\"7359247\">7359247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cook J, Randinitis E, and Wilder BJ, &ldquo;Effect of Food on the Bioavailability of 100-mg Dilantin&reg; Kapseals,&rdquo; <i>Neurology</i>, 2001, 57(4):698-700. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/11524482/pubmed\" target=\"_blank\" id=\"11524482\">11524482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erstad BL, &quot;Dosing of Medications in Morbidly Obese Patients in the Intensive Care Unit Setting,&quot; <i>Intensive Care Med</i>, 2004, 30(1):18-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/14625670/pubmed\" target=\"_blank\" id=\"14625670\">14625670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erstad BL, &quot;Which Weight for Weight-Based Dosage Regimens in Obese Patients?&quot; <i>Am J Health Syst Pharm</i>, 2002, 59(21):2105-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/12434728/pubmed\" target=\"_blank\" id=\"12434728\">12434728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guerrini R, &quot;Epilepsy in Children,&quot; <i>Lancet</i>, 2006, 367(9509):499-524.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/16473127/pubmed\" target=\"_blank\" id=\"16473127\">16473127</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hanhan UA, Fiallos MR, Orlowski JP. Status epilepticus. <i>Pediatr Clin North Am</i>. 2001;48(3):683-694. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/11411300 /pubmed\" target=\"_blank\" id=\"11411300 \">11411300 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and American Epilepsy Society.  <i>Neurology</i>. 2009, 73(2):133-141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/19398681/pubmed\" target=\"_blank\" id=\"19398681\">19398681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update management issues for women with epilepsy-focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009;73(2):142-149.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/19398680/pubmed\" target=\"_blank\" id=\"19398680\">19398680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &quot;Preparing for Pediatric Emergencies: Drugs to Consider,&quot; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;lvi&auml;inen R, &quot;Status Epilepticus Treatment Guidelines,&quot; <i>Epilepsia</i>, 2007, 48(Suppl 8):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18330014/pubmed\" target=\"_blank\" id=\"18330014\">18330014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kerrick JM, Wolff DL, and Graves NM, &quot;Predicting Unbound Phenytoin Concentrations in Patients Receiving Valproic Acid: A Comparison of Two Prediction Methods,&quot; <i>Ann Pharmacother</i>, 1995, 29(5):470-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/7655129/pubmed\" target=\"_blank\" id=\"7655129\">7655129</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kochanek PM, Carney N, Adelson PD, et al, &quot;Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents-Second Edition,&quot; <i>Pediatr Crit Care Med</i>, 2012, 13(Suppl 1):S1-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/22217782/pubmed\" target=\"_blank\" id=\"22217782\">22217782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis RJ, Yee L, Inkelis SH, et al, &quot;Clinical Predictors of Post-Traumatic Seizures in Children With Head Trauma,&quot; <i>Ann Emerg Med</i>, 1993, 22(7):1114-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/8517559/pubmed\" target=\"_blank\" id=\"8517559\">8517559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lowenstein DH, &ldquo;Treatment Options for Status Epilepticus,&rdquo; <i>Curr Opin Pharmacol</i>, 2005, 5(3):334-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/15907922/pubmed\" target=\"_blank\" id=\"15907922\">15907922</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mansur LI, Murrow RW, Garrelts JC, et al, &quot;Rebound of Plasma Free Phenytoin Concentration Following Plasmapheresis in a Patient With Thrombotic Thrombocytopenic Purpura,&quot; <i>Ann Pharmacother</i>, 1995, 29(6):592-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/7663032/pubmed\" target=\"_blank\" id=\"7663032\">7663032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meek PD, Davis SN, Collins DM, et al, &quot;Guidelines for Nonemergency Use of Parenteral Phenytoin Products: Proceedings of an Expert Panel Consensus Process. Panel on Nonemergency Use of Parenteral Phenytoin Products,&quot; <i>Arch Intern Med</i>, 1999, 159(22):2639-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/10597754/pubmed\" target=\"_blank\" id=\"10597754\">10597754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. <i>Pediatrics</i>. 2008;122(2):398-417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18676559/pubmed\" target=\"_blank\" id=\"18676559\">18676559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery LA, Hanrahan K, Kottman K, et al. Guideline for I.V. infiltrations in pediatric patients. <i>Pediatr Nurs</i>. 1999;25(2):167-169, 173-180. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/10532013/pubmed\" target=\"_blank\" id=\"10532013\">10532013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i>. 2008;49(7):1239-1276.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18397299/pubmed\" target=\"_blank\" id=\"18397299\">18397299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pfeifle CE, Adler DS, and Gannaway WL, &quot;Phenytoin Sodium Solubility in Three Intravenous Solutions,&quot; <i>Am J Hosp Pharm</i>, 1981, 38(3):358-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/7223749/pubmed\" target=\"_blank\" id=\"7223749\">7223749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shearer P and Riviello J, &quot;Generalized Convulsive Status Epilepticus in Adults and Children: Treatment Guidelines and Protocols,&quot; <i>Emerg Med Clin North Am</i>, 2011, 29(1):51-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/21109102/pubmed\" target=\"_blank\" id=\"21109102\">21109102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suzuki Y, Mimaki T, Cox S, et al, &ldquo;Phenytoin Age-Dose-Concentration Relationship in Children,&rdquo; <i>Ther Drug Monit</i>, 1994, 16(2):145-50. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/8009561/pubmed\" target=\"_blank\" id=\"8009561\">8009561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner CL, Greer FR, American Academy of Pediatrics Section on Breastfeeding, American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. <i>Pediatrics</i>. 2008;122(5):1142-1152.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18977996/pubmed\" target=\"_blank\" id=\"18977996\">18977996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilder BJ, Leppik I, Hietpas TJ, et al, &ldquo;Effect of Food on Absorption of Dilantin&reg; Kapseals and Mylan Extended Phenytoin Sodium Capsules,&rdquo; <i>Neurology</i>, 2001, 57(4):582-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/ 11524464 /pubmed\" target=\"_blank\" id=\" 11524464 \"> 11524464 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young KD, Okada PJ, Sokolove PE, et al, &quot;A Randomized, Double-Blinded, Placebo-Controlled Trial of Phenytoin for the Prevention of Early Posttraumatic Seizures in Children With Moderate to Severe Blunt Head Injury,&quot; <i>Ann Emerg Med</i>, 2004, 43(4):435-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/15039684/pubmed\" target=\"_blank\" id=\"15039684\">15039684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12702 Version 252.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F11284327\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F209593\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F209594\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054953\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444747\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054946\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F209562\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F209547\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F26964803\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11441305\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054958\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133436\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F209585\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054957\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F209653\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F209650\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F209570\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F209551\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26059987\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F209639\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F209556\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F209588\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F209573\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054952\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1054956\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F209550\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F209569\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F209572\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F209576\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12702|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">Phenytoin: Drug information</a></li><li><a href=\"topic.htm?path=phenytoin-patient-drug-information\" class=\"drug drug_patient\">Phenytoin: Patient drug information</a></li></ul></div></div>","javascript":null}